In the ninth episode, Nicholas and Lana unpack several longevity launches making waves, and why regulatory clearance, novelty, and clinical data are 3 separate things brands shouldn't blur together.

TriNutra is presenting new data on its standardized black seed oil ingredient at SupplySide Global, adding to a growing body of research on how gut bacteria and the body's stress response may influence each other.

A randomized, crossover trial found that ThymoDream, a standardized black cumin seed oil, raised endogenous melatonin levels and improved several sleep measures over 7 nights, with lower reported daytime sleepiness than synthetic melatonin.

Formulators are moving toward botanicals like ashwagandha, bacopa, saffron, and PEA that target the stress, cortisol, and nervous-system pathways behind restless nights.

Why responsible innovation means asking whether yesterday's formulations still reflect today's best science—not just launching the next new ingredient.

A randomized crossover trial finds that formulation, not just dose, determines how much of the hops-derived compound xanthohumol actually reaches the bloodstream.

A new 12-week trial adds controlled data to a question that matters for manufacturers positioning creatine beyond sports nutrition: does its muscle-building evidence hold up in adults over 45, including those not following a structured exercise program?

Piping Rock Health Products has launched a 300-mg NMN gummy under its Vitafusion brand, arriving less than a year after the FDA reversed its position on whether the ingredient could legally be sold as a dietary supplement.